TY - JOUR AU - Kettunen, K. AU - Boström, P. J. AU - Lamminen, T. PY - 2019 DA - 2019// TI - Personalized drug sensitivity screening for bladder cancer using conditionally reprogrammed patient-derived cells JO - Eur Urol VL - 76 UR - https://doi.org/10.1016/j.eururo.2019.06.016 DO - 10.1016/j.eururo.2019.06.016 ID - Kettunen2019 ER - TY - JOUR AU - Lehtomaki, K. I. AU - Lahtinen, L. I. AU - Rintanen, N. PY - 2019 DA - 2019// TI - Clonal evolution of MEK/MAPK pathway activating mutations in a metastatic colorectal cancer case JO - Anticancer Res VL - 39 UR - https://doi.org/10.21873/anticanres.13791 DO - 10.21873/anticanres.13791 ID - Lehtomaki2019 ER - TY - JOUR AU - Arjonen, A. AU - Mäkelä, R. AU - Härmä, V. PY - 2020 DA - 2020// TI - Image-based ex vivo drug screen to assess targeted therapies in recurrent thymoma JO - Lung Cancer VL - 145 UR - https://doi.org/10.1016/j.lungcan.2020.04.036 DO - 10.1016/j.lungcan.2020.04.036 ID - Arjonen2020 ER - TY - JOUR AU - Billingham, L. AU - Malottki, K. AU - Steven, N. PY - 2016 DA - 2016// TI - Research methods to change clinical practice for patients with rare cancers JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(15)00396-4 DO - 10.1016/S1470-2045(15)00396-4 ID - Billingham2016 ER - TY - JOUR AU - Pauli, C. AU - Hopkins, B. D. AU - Prandi, D. PY - 2017 DA - 2017// TI - Personalized in vitro and in vivo cancer models to guide precision medicine JO - Cancer Discov VL - 7 UR - https://doi.org/10.1158/2159-8290.CD-16-1154 DO - 10.1158/2159-8290.CD-16-1154 ID - Pauli2017 ER - TY - JOUR AU - Paner, G. P. AU - Lopez-Beltran, A. AU - Sirohi, D. AU - Amin, M. B. PY - 2016 DA - 2016// TI - Updates in the pathologic diagnosis and classification of epithelial neoplasms of urachal origin JO - Adv Anat Pathol VL - 23 UR - https://doi.org/10.1097/PAP.0000000000000110 DO - 10.1097/PAP.0000000000000110 ID - Paner2016 ER - TY - JOUR AU - Gopalan, A. AU - Sharp, D. S. AU - Fine, S. W. PY - 2009 DA - 2009// TI - Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation JO - Am J Surg Pathol VL - 33 UR - https://doi.org/10.1097/PAS.0b013e31819aa4ae DO - 10.1097/PAS.0b013e31819aa4ae ID - Gopalan2009 ER - TY - JOUR AU - Ashley, R. A. AU - Inman, B. A. AU - Sebo, T. J. AU - Leibovich, B. C. AU - Blute, M. L. AU - Kwon, E. D. PY - 2006 DA - 2006// TI - Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy JO - Cancer. VL - 107 UR - https://doi.org/10.1002/cncr.22060 DO - 10.1002/cncr.22060 ID - Ashley2006 ER - TY - JOUR AU - Yanagihara, Y. AU - Tanji, N. AU - Miura, N. PY - 2013 DA - 2013// TI - Modified FOLFOX6 chemotherapy in patients with metastatic urachal cancer JO - Chemotherapy. VL - 59 UR - https://doi.org/10.1159/000362400 DO - 10.1159/000362400 ID - Yanagihara2013 ER - TY - JOUR AU - Mylonas, K. S. AU - Malley, P. O. AU - Ziogas, I. A. AU - El-Kabab, L. AU - Nasioudis, D. PY - 2017 DA - 2017// TI - Malignant urachal neoplasms: a population-based study and systematic review of literature JO - Urol Oncol VL - 35 UR - https://doi.org/10.1016/j.urolonc.2016.07.021 DO - 10.1016/j.urolonc.2016.07.021 ID - Mylonas2017 ER - TY - JOUR AU - Nagumo, Y. AU - Kojima, T. AU - Shiga, M. PY - 2020 DA - 2020// TI - Clinicopathological features of malignant urachal tumor: a hospital-based cancer registry data in Japan JO - Int J Urol VL - 2 UR - https://doi.org/10.1111/iju.14154 DO - 10.1111/iju.14154 ID - Nagumo2020 ER - TY - JOUR AU - Hamilou, Z. AU - North, S. AU - Canil, C. PY - 2020 DA - 2020// TI - Management of urachal cancer: a consensus statement by the Canadian Urological Association and genitourinary medical oncologists of Canada JO - Can Urol Assoc J VL - 3 ID - Hamilou2020 ER - TY - JOUR AU - Szarvas, T. AU - Módos, O. AU - Niedworok, C. AU - Reis, H. AU - Szendröi, A. AU - Szász, M. A. PY - 2016 DA - 2016// TI - Clinical, prognostic, and therapeutic aspects of urachal carcinoma-a comprehensive review with meta-analysis of 1,010 cases JO - Urol Oncol VL - 34 UR - https://doi.org/10.1016/j.urolonc.2016.04.012 DO - 10.1016/j.urolonc.2016.04.012 ID - Szarvas2016 ER - TY - JOUR AU - Kanamaru, T. AU - Iguchi, T. AU - Yukimatsu, N. AU - Shimizu, Y. AU - Kohyama, Y. AU - Tachibana, H. PY - 2015 DA - 2015// TI - A case of metastatic urachal carcinoma treated with FOLFIRI (irinotecan and 5-fluorouracil/leucovorin) plus bevacizumab JO - Urol Case Rep VL - 3 UR - https://doi.org/10.1016/j.eucr.2014.11.004 DO - 10.1016/j.eucr.2014.11.004 ID - Kanamaru2015 ER - TY - JOUR AU - Tran, B. AU - McKendrick, J. PY - 2010 DA - 2010// TI - Metastatic urachal cancer responding to FOLFOX chemotherapy JO - Can J Urol VL - 17 ID - Tran2010 ER - TY - JOUR AU - Yazawa, S. AU - Kikuchi, E. AU - Takeda, T. PY - 2012 DA - 2012// TI - Surgical and chemotherapeutic options for urachal carcinoma: report of ten cases and literature review JO - Urol Int VL - 88 UR - https://doi.org/10.1159/000334414 DO - 10.1159/000334414 ID - Yazawa2012 ER - TY - JOUR AU - Hong, S. H. AU - Kim, J. C. AU - Hwang, T. K. PY - 2007 DA - 2007// TI - Laparoscopic partial cystectomy with en bloc resection of the urachus for urachal adenocarcinoma JO - Int J Urol VL - 14 UR - https://doi.org/10.1111/j.1442-2042.2007.01855.x DO - 10.1111/j.1442-2042.2007.01855.x ID - Hong2007 ER - TY - JOUR AU - Mertens, L. S. AU - Behrendt, M. A. AU - Mehta, A. M. PY - 2019 DA - 2019// TI - Long-term survival after cytoreductive surgery and hyperthermicintraperitoneal chemotherapy (HIPEC) for patients with peritonealmetastases of urachal cancer JO - Eur J Surg Oncol VL - 45 UR - https://doi.org/10.1016/j.ejso.2019.03.034 DO - 10.1016/j.ejso.2019.03.034 ID - Mertens2019 ER - TY - JOUR AU - Siefker-Radtke, A. O. AU - Gee, J. AU - Shen, Y. PY - 2003 DA - 2003// TI - Multimodality management of urachal carcinoma: the M. D. Anderson cancer center experience JO - J Urol VL - 169 UR - https://doi.org/10.1097/01.ju.0000054646.49381.01 DO - 10.1097/01.ju.0000054646.49381.01 ID - Siefker-Radtke2003 ER - TY - JOUR AU - Molina, J. R. AU - Quevedo, J. F. AU - Furth, A. F. AU - Richardson, R. L. AU - Zincke, H. AU - Burch, P. A. PY - 2007 DA - 2007// TI - Predictors of survival from urachal cancer: a Mayo Clinic study of 49 cases JO - Cancer. VL - 110 UR - https://doi.org/10.1002/cncr.23070 DO - 10.1002/cncr.23070 ID - Molina2007 ER - TY - JOUR AU - Sirintrapun, S. J. AU - Ward, M. AU - Woo, J. PY - 2014 DA - 2014// TI - High-stage urachal adenocarcinoma can be associated with microsatellite instability and KRAS mutations JO - Hum Pathol VL - 45 UR - https://doi.org/10.1016/j.humpath.2013.09.008 DO - 10.1016/j.humpath.2013.09.008 ID - Sirintrapun2014 ER - TY - JOUR AU - Collazo-Lorduy, A. AU - Castillo-Martin, M. AU - Wang, L. PY - 2016 DA - 2016// TI - Urachal carcinoma shares genomic alterations with colorectal carcinoma and may respond to epidermal growth factor inhibition JO - Eur Urol VL - 70 UR - https://doi.org/10.1016/j.eururo.2016.04.037 DO - 10.1016/j.eururo.2016.04.037 ID - Collazo-Lorduy2016 ER - TY - JOUR AU - Reis, H. AU - Vos, K. E. AU - Niedworok, C. PY - 2018 DA - 2018// TI - Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas JO - Int J Cancer VL - 143 UR - https://doi.org/10.1002/ijc.31547 DO - 10.1002/ijc.31547 ID - Reis2018 ER - TY - JOUR AU - Loh, K. P. AU - Mondo, E. AU - Hansen, E. A. PY - 2016 DA - 2016// TI - Targeted therapy based on tumor genomic analyses in metastatic urachal carcinoma JO - Clin Genitourin Cancer VL - 14 UR - https://doi.org/10.1016/j.clgc.2016.03.013 DO - 10.1016/j.clgc.2016.03.013 ID - Loh2016 ER - TY - JOUR AU - Doll, S. AU - Kriegmair, M. C. AU - Santos, A. PY - 2018 DA - 2018// TI - Rapid proteomic analysis for solid tumors reveals LSD1 as a drug target in an end-stage cancer patient JO - Mol Oncol VL - 12 UR - https://doi.org/10.1002/1878-0261.12326 DO - 10.1002/1878-0261.12326 ID - Doll2018 ER - TY - JOUR AU - Módos, O. AU - Reis, H. AU - Niedworok, C. PY - 2016 DA - 2016// TI - Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance JO - Oncotarget. VL - 7 UR - https://doi.org/10.18632/oncotarget.9828 DO - 10.18632/oncotarget.9828 ID - Módos2016 ER - TY - JOUR AU - Landrum, M. J. AU - Lee, J. M. AU - Benson, M. PY - 2018 DA - 2018// TI - ClinVar: improving access to variant interpretations and supporting evidence JO - Nucleic Acids Res VL - 46 UR - https://doi.org/10.1093/nar/gkx1153 DO - 10.1093/nar/gkx1153 ID - Landrum2018 ER - TY - JOUR AU - Chou, T. C. PY - 2010 DA - 2010// TI - Drug combination studies and their synergy quantification using the Chou–Talalay method JO - Cancer Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-09-1947 DO - 10.1158/0008-5472.CAN-09-1947 ID - Chou2010 ER - TY - JOUR AU - Sahu, K. K. AU - Pandey, D. AU - Mishra, A. K. PY - 2019 DA - 2019// TI - Mystery of neck lump: an uncommon presentation of urachal cancer JO - BMJ Case Rep VL - 12 UR - https://doi.org/10.1136/bcr-2019-230215 DO - 10.1136/bcr-2019-230215 ID - Sahu2019 ER - TY - JOUR AU - Labarge, M. A. AU - Garbe, J. C. AU - Stampfer, M. R. PY - 2013 DA - 2013// TI - Processing of human reduction mammoplasty and mastectomy tissues for cell culture JO - J Vis Exp VL - 71 ID - Labarge2013 ER - TY - JOUR AU - Westley, J. W. AU - Evans, R. H. AU - Sello, L. H. AU - Troupe, N. AU - Liu, C. AU - Miller, P. A. PY - 1981 DA - 1981// TI - Isolation of novel antibiotics X 14667A and X-14667B from Streptomyces cinnamonensis subsp. urethanofaciens and their characterization as 2-phenethylurethanes of monensins B and a JO - J Antibiot (Tokyo) VL - 34 UR - https://doi.org/10.7164/antibiotics.34.1248 DO - 10.7164/antibiotics.34.1248 ID - Westley1981 ER - TY - JOUR AU - Ketola, K. AU - Vainio, P. AU - Fey, V. AU - Kallioniemi, O. AU - Iljin, K. PY - 2010 DA - 2010// TI - Monensin is a potent inducer of oxidative stress and inhibitor of androgen signaling leading to apoptosis in prostate cancer cells JO - Mol Cancer Ther VL - 9 UR - https://doi.org/10.1158/1535-7163.MCT-10-0368 DO - 10.1158/1535-7163.MCT-10-0368 ID - Ketola2010 ER - TY - JOUR AU - Niepel, M. AU - Hafner, M. AU - Mills, C. E. PY - 2019 DA - 2019// TI - A multi-center study on the reproducibility of drug-response assays in mammalian cell lines JO - Cell Syst VL - 9 UR - https://doi.org/10.1016/j.cels.2019.06.005 DO - 10.1016/j.cels.2019.06.005 ID - Niepel2019 ER - TY - JOUR AU - Degirmenci, U. AU - Wang, M. AU - Hu, J. PY - 2020 DA - 2020// TI - Targeting aberrant RAS/RAF/MEK/ERK signaling for cancer therapy JO - Cells VL - 9 UR - https://doi.org/10.3390/cells9010198 DO - 10.3390/cells9010198 ID - Degirmenci2020 ER - TY - JOUR AU - Zawistowski, J. S. AU - Bevill, S. M. AU - Goulet, D. R. PY - 2017 DA - 2017// TI - Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex JO - Cancer Discov VL - 7 UR - https://doi.org/10.1158/2159-8290.CD-16-0653 DO - 10.1158/2159-8290.CD-16-0653 ID - Zawistowski2017 ER - TY - JOUR AU - Mullard, A. PY - 2015 DA - 2015// TI - NCI-MATCH trial pushes cancer umbrella trial paradigm JO - Nat Rev Drug Discov VL - 14 UR - https://doi.org/10.1038/nrd4694 DO - 10.1038/nrd4694 ID - Mullard2015 ER - TY - JOUR AU - Snijder, B. AU - Vladimer, G. I. AU - Krall, N. PY - 2017 DA - 2017// TI - Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study JO - Lancet Haematol VL - 4 UR - https://doi.org/10.1016/S2352-3026(17)30208-9 DO - 10.1016/S2352-3026(17)30208-9 ID - Snijder2017 ER - TY - JOUR AU - Puca, L. AU - Bareja, R. AU - Prandi, D. PY - 2018 DA - 2018// TI - Patient derived organoids to model rare prostate cancer phenotypes JO - Nat Commun VL - 9 UR - https://doi.org/10.1038/s41467-018-04495-z DO - 10.1038/s41467-018-04495-z ID - Puca2018 ER - TY - JOUR AU - Jeppesen, M. AU - Hagel, G. AU - Glenthoj, A. PY - 2017 DA - 2017// TI - Short-term spheroid culture of primary colorectal cancer cells as an in vitro model for personalizing cancer medicine JO - PLoS One VL - 12 UR - https://doi.org/10.1371/journal.pone.0183074 DO - 10.1371/journal.pone.0183074 ID - Jeppesen2017 ER - TY - JOUR AU - Brijwani, N. AU - Jain, M. AU - Dhandapani, M. PY - 2017 DA - 2017// TI - Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on notch and Erbb2 JO - Sci Rep VL - 7 UR - https://doi.org/10.1038/s41598-017-01566-x DO - 10.1038/s41598-017-01566-x ID - Brijwani2017 ER - TY - JOUR AU - Powley, I. R. AU - Patel, M. AU - Miles, G. PY - 2020 DA - 2020// TI - Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery JO - Br J Cancer VL - 122 UR - https://doi.org/10.1038/s41416-019-0672-6 DO - 10.1038/s41416-019-0672-6 ID - Powley2020 ER -